27 August 2021 - Late treatment study
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4 (Peer Reviewed)
RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
time to improvement, 37.1% lower, RR 0.63, p = 0.01, treatment 107, control 49, adjusted per study, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
|
time to improvement, 58.5% lower, RR 0.41, p = 0.01, treatment 47, control 13, adjusted per study, <5 days from onset of fever, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Shinkai et al., 8/27/2021, Single Blind Randomized Controlled Trial, Japan, Asia, peer-reviewed, 39 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.